Hyundai Bioscience leads in the repurposing of Niclosamide

By markets.businessinsider.com4 days ago

AD

SEOUL, South Korea, April 8, 2021 /PRNewswire/ -- A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection (COVID-19), was published in the world-renowned SCI (Science and Technology Journal Citation Index)-level international journal and is attracting international attention.

Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on April 8 that CNPharm, its major shareholding bio tech company, published a research paper that proves the successful repurposing (or repositioning) of Niclosamide for COVID-19 treatment by using a drug delivery system (DDS), an original technology of CNPharm. The paper was recently listed in Polymers, a world-renowned scientific journal in the field of polymer science. CNPharm also filed international patent applications on this DDS technology for repurposing Niclosamide as COVID-19 treatment.

Although Niclosamide has been found to be effective for various diseases so far, this is the first time that a paper demonstrating drug repurposing through various study results has been published in an SCI-level international journal. This means that the international pharmaceutical community has recognized that CNPharm, the parent company of Hyundai Bioscience, is leading the way to repurpose the anthelmintic drug. As a result, international interest in CP-COV03, an oral drug to combat COVID-19 developed by CNPharm, is expected to increase.

In the paper titled 'NiclosamideClay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment', an experimental result was also revealed that the bioavailability of the repurposed Niclosamide formulation using CNPharm's cationic drug delivery system (DDS) was increased by 60% compared to Yomesan, the current anthelmintic formulation of Niclosamide.

An official at Hyundai Bioscience stated that this is the first time that Niclosamide's bioavailability improvement for drug repurposing has been published in an international journal. In addition to COVID-19, we plan to expand the scope of repurposing so that it can be applied to various intractable diseases such as metastatic cancer and resistant cancer.In particular, it was reported that COVID-19 variants, which have recently raised concerns of the international community, can be suppressed by repurposed Niclosamide using CNPharm's drug delivery system. A follow-up study is in progress.

Continue read on businessinsider.com